scispace - formally typeset
A

Anna N. Tevyashova

Researcher at D. Mendeleev University of Chemical Technology of Russia

Publications -  41
Citations -  443

Anna N. Tevyashova is an academic researcher from D. Mendeleev University of Chemical Technology of Russia. The author has contributed to research in topics: Olivomycin & Galactomannan. The author has an hindex of 11, co-authored 38 publications receiving 310 citations. Previous affiliations of Anna N. Tevyashova include National University of Science and Technology & Hungarian Academy of Sciences.

Papers
More filters
Journal ArticleDOI

Structure-Antifungal Activity Relationships of Polyene Antibiotics of the Amphotericin B Group

TL;DR: Compounds, namely, l-glutamate of 2-(N,N-dimethylamino)ethyl amide of S44HP (compound 2j), with high antifungal activity that were comparable in in vitro and in vivo tests to AMB and that have better toxicological properties are discovered.
Journal ArticleDOI

Formation of squaric acid amides of anthracycline antibiotics. Synthesis and cytotoxic properties

TL;DR: Of the prepared compounds, anthracycline glycoside antibiotics 1-3 with the squaric acid ester 4 was the most active on MCF-7 human mammary adenocarcinoma cells.
Journal ArticleDOI

Design of dual action antibiotics as an approach to search for new promising drugs

TL;DR: The review is devoted to the latest achievements in the design of dual action antibiotics ?
Journal ArticleDOI

New conjugates of polyene macrolide amphotericin B with benzoxaboroles: synthesis and properties

TL;DR: The di-modified conjugate 2-(N,N-dimethylamino)ethylamide of 3′-N-[3-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-7-yl)propanoyl] AmB showed the best combination of a high antifungal activity with a low cytotoxic and hemolytic potency.
Journal ArticleDOI

Modification of olivomycin A at the side chain of the aglycon yields the derivative with perspective antitumor characteristics

TL;DR: The therapeutic effects of this derivative were achievable at tolerable concentrations, suggesting that modifications of the aglycon's side chain, namely, its shortening to methoxyacetic residue and blocking of free carboxyl group, are straightforward for the design of therapeutically applicable derivatives of olivomycin A.